StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Oncology Portfolio Total [legacy incl. Oncology by Year

Oncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M) ($M)

QuarterlyAnnual

Pfizer Oncology Portfolio Total [legacy incl. Oncology: $16,834M in FY2025, up 7.8% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
16,834
Period ended Dec 31, 2025
Change on a year earlier
+7.8%
15,612 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Oncology | $ | 16,834 | $ | 15,612 | 8% | 8% | $ | 12,512 | $ | 11,567 | 8% | $ | 4,321 | $ | 4,045 | 7% | 6%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

In Q1 2026, Oncology Biosimilars moved from Oncology into the new Global Hospital & Biosimilars portfolio.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M) ($M)Year on yearSource
FY2025Dec 31, 202516,834+7.8%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 202415,612+25.4%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 202312,450+617.6%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20221,735-19.2%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021Dec 31, 20212,148+23.0%Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020Dec 31, 20201,746+4.7%Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019Dec 31, 20191,667+16.1%Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2018Dec 31, 20181,436-76.3%Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2017Dec 31, 20176,056+32.7%Form 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗
FY2016Dec 31, 20164,563–Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗

Breakdown

What makes up oncology Portfolio Total [legacy incl. Oncology

Cite this data

StockData. (2026). Pfizer Oncology Portfolio Total [legacy incl. Oncology ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/port-leg-onc-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.